AIDS treatment with novel anti-HIV compounds improved by nanotechnology

AAPS Journal

Volumn 12, Issue 3, 2010, Pages 272-278

  Ma, Xiaowei ^a,h   Wang, Dongliang ^a,h   Wu, Yan ^a,h   Ho, Rodney J Y ^b   Jia, Lee ^c   Guo, Peixuan ^d   Hu, Liming ^e   Xing, Gengmei ^f   Zeng, Yi ^e,g   Liang, Xing Jie ^a,h  

^a NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY   (China)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d University of Cincinnati   (United States)

^e BEIJING UNIVERSITY OF TECHNOLOGY   (China)

^f INSTITUTE OF HIGH ENERGY PHYSICS   (China)

^g National Institute for Communicable Disease Control and Prevention   (China)

^h INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

AIDS treatment; anti AIDS drug development; nanomedicine; nanotechnology

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; CARBENDAZIM; E 809; E 823; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; GOLD NANOPARTICLE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INDINAVIR; INTEGRASE INHIBITOR; LAMIVUDINE; LIPOFECTAMINE; NANOMATERIAL; NB 2; NB 64; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NSC 158393; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; THIADIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE; DRUG CARRIER;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; CHINA; CONFERENCE PAPER; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG FORMULATION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SYNTHESIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; NANOBIOTECHNOLOGY; NANOMEDICINE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; TIME TO MAXIMUM PLASMA CONCENTRATION; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; NANOTECHNOLOGY;

ANTI-HIV AGENTS; DRUG CARRIERS; HIV INFECTIONS; HIV-1; HUMANS; NANOTECHNOLOGY;

EID: 77955977615     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-010-9187-z     Document Type: Conference Paper

References (26)

1. L Jia 2005 Nanoparticle formulation increases oral bioavailability of poorly soluble drugs: approaches experimental evidences and theory Curr Nanosci 1 237 243 10.2174/157341305774642939 1:CAS:528:DC%2BD2MXhtF2msLnM 19865587
2. L Jia H Wong C Cerna SD Weitman 2002 Effect of nanonization on absorption of 301029: ex vivo and in vivo pharmacokinetic correlations determined by liquid chromatography/mass spectrometry Pharm Res 19 1091 1096 10.1023/A:1019829622088 1:CAS:528:DC%2BD38XmtlGhurc%3D 12240933
3. L Jia H Wong Y Wang M Garza SD Weitman 2003 Carbendazim: disposition, cellular permeability, metabolite identification, and pharmacokinetic comparison with its nanoparticle J Pharm Sci 92 161 172 10.1002/jps.10272 1:CAS:528:DC%2BD3sXisVamtA%3D%3D 12486692
4. F Zhang JE Haberer Y Wang, et al. 2007 The Chinese free antiretroviral treatment program: challenges and responses AIDS 21 Suppl 8 S143 S148 10.1097/01.aids.0000304710.10036.2b 18172383
5. F Zhang Z Dou Y Ma, et al. 2009 Five-year outcomes of the China National Free Antiretroviral Treatment Program Ann Intern Med 151 241 251 19687491 W-52
6. L Kinman SJ Brodie CC Tsai, et al. 2003 Lipid-drug association enhanced HIV-1 protease inhibitor indinavir localization in lymphoid tissues and viral load reduction: a proof of concept study in HIV-2287-infected macaques J Acquir Immune Defic Syndr 34 387 397 10.1097/00126334-200312010-00005 1:CAS:528:DC%2BD3sXovV2lt7s%3D 14615656
7. SU Choi T Bui RJ Ho 2008 pH-dependent interactions of indinavir and lipids in nanoparticles and their ability to entrap a solute J Pharm Sci 97 931 943 10.1002/jps.21020 1:CAS:528:DC%2BD1cXhvFaksLk%3D 17546665
8. P Guo S Grimes D Anderson 1986 A defined system for in vitro packaging of DNA-gp3 of the Bacillus subtilis bacteriophage phi 29 Proc Natl Acad Sci U S A. 83 3505 3509 10.1073/pnas.83.10.3505 1:CAS:528:DyaL28XkslCntb8%3D 3458193
9. PX Guo S Erickson D Anderson 1987 A small viral RNA is required for in vitro packaging of bacteriophage phi 29 DNA Science 236 690 694 10.1126/science.3107124 1:CAS:528:DyaL2sXkt1Snt7g%3D 3107124
10. P Guo C Zhang C Chen K Garver M Trottier 1998 Inter-RNA interaction of phage phi29 pRNA to form a hexameric complex for viral DNA transportation Mol Cell 2 149 1455 10.1016/S1097-2765(00)80124-0 1:CAS:528:DyaK1cXltVCjtbc%3D 9702202
11. S Guo F Huang P Guo 2006 Construction of folate-conjugated pRNA of bacteriophage phi29 DNA packaging motor for delivery of chimeric siRNA to nasopharyngeal carcinoma cells Gene Ther 13 814 820 10.1038/sj.gt.3302856 1:CAS:528:DC%2BD28XktVGktbc%3D 16482206
12. S Guo N Tschammer S Mohammed P Guo 2005 Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA Hum Gene Ther 16 1097 1109 10.1089/hum.2005.16.1097 1:CAS:528:DC%2BD2MXpvVKjtLo%3D 16149908
13. S Hoeprich Q Zhou S Guo, et al. 2003 Bacterial virus phi29 pRNA as a hammerhead ribozyme escort to destroy hepatitis B virus Gene Ther 10 1258 1267 10.1038/sj.gt.3302002 1:CAS:528:DC%2BD3sXltlCqsLc%3D 12858191
14. A Khaled S Guo F Li P Guo 2005 Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology Nano Lett 5 1797 1808 10.1021/nl051264s 1:CAS:528:DC%2BD2MXpvFCiuro%3D 16159227
15. D Wendell P Jing J Geng, et al. 2009 Translocation of double-stranded DNA through membrane-adapted phi29 motor protein nanopores Nat Nanotechnol 4 765 772 10.1038/nnano.2009.259 1:CAS:528:DC%2BD1MXhtlygsb7O 19893523
16. HM Zhang Y Su S Guo, et al. 2009 Targeted delivery of anti-coxsackievirus siRNAs using ligand-conjugated packaging RNAs Antiviral Res 83 307 316 10.1016/j.antiviral.2009.07.005 1:CAS:528:DC%2BD1MXhtVSisb%2FP 19616030
17. An Z, Tang W, Wu M, Jiao Z, Stucky GD. Heterofunctional polymers and core-shell nanoparticles via cascade aminolysis/Michael addition and alkyne-azide click reaction of RAFT polymers. Chem Commun (Camb). 2008; 6501-3.
18. C Aoneng L Zhen C Saisai, et al. 2009 A facile one-step method to produce graphene-CdS quantum dot nanocomposites as promising optoelectronic materials Adv Materials. 22 103 106
19. E De Clercq 2009 Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV Int J Antimicrob Agents 33 307 320 10.1016/j.ijantimicag.2008.10.010 19108994
20. M Liu XJ Cong P Li JJ Tan WZ Chen CX Wang 2009 Study on the inhibitory mechanism and binding mode of the hydroxycoumarin compound NSC158393 to HIV-1 integrase by molecular modeling Biopolymers 91 700 709 10.1002/bip.21211 1:CAS:528:DC%2BD1MXovFyit7c%3D 19382173
21. JJ Tan WZ Chen CX Wang 2006 Investigating interactions between HIV-1 gp41 and inhibitors by molecular dynamics simulation and MM-PBSA/GBSA calculations J Mol Struct (Thoechem) 766 77 82 10.1016/j.theochem.2006.02.022 1:CAS:528:DC%2BD28XotFWlsr8%3D
22. Y Zhuo R Kong XJ Cong WZ Chen CX Wang 2008 Three-dimensional QSAR analyses of 1, 3, 4-trisubstituted pyrrolidine-based CCR5 receptor inhibitors Eur J Med Chem 43 2724 2734 10.1016/j.ejmech.2008.01.040 1:CAS:528: DC%2BD1cXhsVKhtrjK 18538451
23. ZG Luo CC Zeng LF Yang HQ He CX Wang LM Hu 2009 Synthesis of 6-sulfamoyl-4-oxoquinoline-3-carboxylic acid derivatives as integrase antagonists with anti-HIV activity Chinese Chemical Letters 20 789 792 10.1016/j.cclet.2009.03.014 1:CAS:528:DC%2BD1MXhtVeltb3L
24. YS Xu CC Zeng ZG Jiao LM Hu RG Zhong 2009 Design, synthesis and anti-HIV integrase evaluation of 4-oxo-4H-quinolizine-3-carboxylic acid derivatives Molecules 14 868 883 10.3390/molecules14020868 1:CAS:528:DC%2BD1MXislOqu7g%3D 19255545
25. A Michienzi D Castanotto N Lee S Li JA Zaia JJ Rossi 2003 RNA-mediated inhibition of HIV in a gene therapy setting Ann N Y Acad Sci 1002 63 71 10.1196/annals.1281.008 1:CAS:528:DC%2BD2cXisFKhs7w%3D 14751823
26. GJ Hannon JJ Rossi 2004 Unlocking the potential of the human genome with RNA interference Nature 431 371 378 10.1038/nature02870 1:CAS:528: DC%2BD2cXnsFaiu7s%3D 15372045